Assertio Holdings' Q1 Revenue Plummets to $9.93M, EPS Loss Widens to $(2.93)
ASRT has more than doubled off its 52-week low of $8.61 on light trading volume (0.4× avg).
Summary
Assertio Holdings reported significantly weaker first-quarter 2026 results, with revenue plummeting to $9.93 million from $26.49 million in the prior year, and a diluted loss per share widening to $(2.93) from $(2.12). This substantial decline was primarily driven by sharply lower ROLVEDON sales due to distributor channel timing and front-loading in Q3 2025. While the company's stock is currently trading near its 52-week high, largely buoyed by the ongoing amended merger agreement with Garda Therapeutics as seen in recent timeline events, these poor operational results highlight the challenges facing the core business. A professional trader would need to be aware of this significant deterioration in standalone performance, even as the merger progresses, to fully assess the company's intrinsic value and the implications should the deal face any unexpected hurdles. The company expects a ROLVEDON relaunch to normalize volumes in Q2 2026, which will be a key factor to watch.
At the time of this announcement, ASRT was trading at $22.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145M. The 52-week trading range was $8.61 to $22.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.